237 related articles for article (PubMed ID: 21169248)
21. [New therapeutic strategies in oncology].
Bohuon C
Ann Pharm Fr; 2010 Jul; 68(4):203-4. PubMed ID: 20637352
[No Abstract] [Full Text] [Related]
22. Characteristics of and trends in the late-stage biopharmaceutical pipeline.
Nagle PC; Nicita CA; Gerdes LA; Schmeichel CJ
Am J Manag Care; 2008 Apr; 14(4):226-9. PubMed ID: 18402515
[TBL] [Abstract][Full Text] [Related]
23. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
24. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
LoRusso PM; Boerner SA; Seymour L
Clin Cancer Res; 2010 Mar; 16(6):1710-8. PubMed ID: 20215546
[TBL] [Abstract][Full Text] [Related]
25. Summary of presentations from the 46th annual meeting of the American Society Of Clinical Oncology (2010): focus on developmental therapeutics related to lung cancer.
Morgensztern D; Pennell NA; Subramanian J; Govindan R
Clin Lung Cancer; 2011 Mar; 12(2):94-9. PubMed ID: 21550555
[TBL] [Abstract][Full Text] [Related]
26. Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT).
Booth CM; Calvert AH; Giaccone G; Lobbezoo MW; Seymour LK; Eisenhauer EA
Eur J Cancer; 2008 Jan; 44(1):19-24. PubMed ID: 17890079
[TBL] [Abstract][Full Text] [Related]
27. New adaptive method for phase I trials in oncology.
Meille C; Gentet JC; Barbolosi D; André N; Doz F; Iliadis A
Clin Pharmacol Ther; 2008 Jun; 83(6):873-81. PubMed ID: 17957185
[TBL] [Abstract][Full Text] [Related]
28. Critical assessment of international clinical development programmes for new antihypertensive drugs.
Ménard J
J Hypertens Suppl; 1993 Dec; 11(5):S39-46. PubMed ID: 8158432
[TBL] [Abstract][Full Text] [Related]
29. Phase II clinical trials in oncology: are we hitting the target?
Ang MK; Tan SB; Lim WT
Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
[TBL] [Abstract][Full Text] [Related]
30. Ethical challenges in cancer research in children.
Berg SL
Oncologist; 2007 Nov; 12(11):1336-43. PubMed ID: 18055854
[TBL] [Abstract][Full Text] [Related]
31. Continuous toxicity monitoring in phase II trials in oncology.
Ivanova A; Qaqish BF; Schell MJ
Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous care: a model approach to the perceived conflict between investigational therapy and palliative care.
Meyers FJ; Linder J; Beckett L; Christensen S; Blais J; Gandara DR
J Pain Symptom Manage; 2004 Dec; 28(6):548-56. PubMed ID: 15589080
[TBL] [Abstract][Full Text] [Related]
33. Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
Sharma MR; Maitland ML; Ratain MJ
Cancer J; 2009; 15(5):426-30. PubMed ID: 19826363
[TBL] [Abstract][Full Text] [Related]
34. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
35. An innovative approach to the care of patients on phase I and phase II clinical trials: the role of the experimental therapeutics nurse.
Carlson C; Reilly M; Hitchens A
J Pediatr Oncol Nurs; 2005; 22(6):353-64. PubMed ID: 16216897
[TBL] [Abstract][Full Text] [Related]
36. [Globalization of clinical trials].
Akaza H; Fukuoka M; Ohtsu A; Usami M; Ikeda T; Aiba K; Isonishi S; Ohashi Y; Saijo N; Sone S; Tsukagoshi S; Tsuruo T; Kato M; Mikami O; Dong RP; von Euler M; Blackledge G; Stribling D
Gan To Kagaku Ryoho; 2003 Apr; 30(4):555-65. PubMed ID: 12722692
[TBL] [Abstract][Full Text] [Related]
37. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
38. New science-based endpoints to accelerate oncology drug development.
Kelloff GJ; Sigman CC
Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
[TBL] [Abstract][Full Text] [Related]
39. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
40. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
